eFFECTOR Therapeutics, Inc. Common Stock
EFTR
EFTR was delisted on the 2nd of July, 2024.
17 hedge funds and large institutions have $13.5M invested in eFFECTOR Therapeutics, Inc. Common Stock in 2024 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 14 closing their positions.
145% more capital invested
Capital invested by funds: $5.49M → $13.5M (+$7.96M)
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
32% less funds holding
Funds holding: 25 → 17 (-8)
57% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$2.67M |
| 2 |
SC
Stempoint Capital
New York
|
+$1.59M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$831K |
| 4 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
+$394K |
| 5 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$148K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
-$75.2K |
| 2 |
SIMG
Sonora Investment Management Group
Tucson,
Arizona
|
-$58.4K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$46.7K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$28.8K |
| 5 |
State Street
Boston,
Massachusetts
|
-$14.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Vontobel Holding
Zurich,
Switzerland
| – | -$7.01K | -600 | Closed |
|
27
UBS Group
Zurich,
Switzerland
| – | -$4.25K | -364 | Closed |
|
28
BlackRock
New York
| – | -$259 | -22 | Closed |
|
29
JP Morgan Chase
New York
| – | -$32 | -3 | Closed |
|
30
Bank of America
Charlotte,
North Carolina
| – | -$13 | -1 | Closed |
|
EFTR Hedge Fund Activity: Q1 2024 in Review
17 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in eFFECTOR Therapeutics, Inc. Common Stock (EFTR) for Q1 2024, worth a combined $13.5M — up 145% from $5.49M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of EFTR and 6 opened new positions — a net loss of 8 holders — while 3 trimmed existing stakes and 6 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $2.67M. The largest seller was Northern Trust, exiting entirely with an estimated $75.2K sold.
- 17 institutional investors held eFFECTOR Therapeutics, Inc. Common Stock (EFTR) as of Q1 2024, down from 25 in Q4 2023.
- Funds reported $13.5M of eFFECTOR Therapeutics, Inc. Common Stock stock for Q1 2024, up 145% quarter-over-quarter.
- 6 funds opened new eFFECTOR Therapeutics, Inc. Common Stock positions in Q1 2024 and 14 closed out, a net change of -8 holders.
- The largest eFFECTOR Therapeutics, Inc. Common Stock buyer in Q1 2024 was Armistice Capital, an estimated $2.67M added.
- The largest eFFECTOR Therapeutics, Inc. Common Stock seller in Q1 2024 was Northern Trust, an estimated $75.2K sold.
Based on aggregated 13F filings for Q1 2024.